Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Drugs & Aging
Erschienen in: Drugs & Aging 10/2003

01.08.2003 | Leading Article

Potential Therapeutic Properties of Green Tea Polyphenols in Parkinson’s Disease

verfasst von: Tianhong Pan, Joseph Jankovic, Dr Weidong Le

Erschienen in: Drugs & Aging | Ausgabe 10/2003

Einloggen, um Zugang zu erhalten

Abstract

Tea is one of the most frequently consumed beverages in the world. It is rich in polyphenols, a group of compounds that exhibit numerous biochemical activities. Green tea is not fermented and contains more catechins than black tea or oolong tea. Although clinical evidence is still limited, the circumstantial data from several recent studies suggest that green tea polyphenols may promote health and reduce disease occurrence, and possibly protect against Parkinson’s disease and other neurodegenerative diseases.
Green tea polyphenols have demonstrated neuroprotectant activity in cell cultures and animal models, such as the prevention of neurotoxin-induced cell injury. The biological properties of green tea polyphenols reported in the literature include antioxidant actions, free radical scavenging, iron-chelating properties, 3H-dopamine and 3H-methyl-4-phenylpyridine uptake inhibition, catechol-O-methyl-transferase activity reduction, protein kinase C or extracellular signal-regulated kinases signal pathway activation, and cell survival/cell cycle gene modulation. All of these biological effects may benefit patients with Parkinson’s disease.
Despite numerous studies in recent years, the understanding of the biological activities and health benefits of green tea polyphenols is still very limited. Further in-depth studies are needed to investigate the safety and efficacy of green tea in humans and to determine the different mechanisms of green tea in neuroprotection.
Literatur
1.
2.
Shiota S, Shimizu M, Mizushima T, et al. Marked reduction in the minimum inhibitory concentration (MIC) of beta-lactams in methicillin-resistant Staphylococcus aureus produced by epicatechin gallate, an ingredient of green tea (Camellia sinensis). Biol Pharm Bull 1999; 22: 1388–90PubMedCrossRef
3.
4.
Muramatsu K, Fukuyo M, Hara Y. Effect of green tea catechins on plasma cholesterol level in cholesterol-fed rats. J Nutr Sci Vitaminol (Tokyo) 1986; 32: 613–22CrossRef
5.
Matsumoto N, Ishigaki F, Ishigaki A, et al. Reduction of blood glucose levels by tea catechin. Biosci Biotechnol Biochem 1993; 57: 525–7CrossRef
6.
Hertog M, Feskens E, Kromhout D. Antioxidant flavonols and coronary heart disease risk [letter]. Lancet 1997; 349: 699PubMedCrossRef
7.
Sesso H, Gaziano J, Buring J, et al. Coffee and tea intake and the risk of myocardial infarction. Am J Epidemiol 1999; 149: 162–7PubMedCrossRef
8.
Keli S, Hertog M, Feskens E, et al. Flavonoids, antiowciant vitamins and risk of stroke: the Zutphen Study. Arch Intern Med 1995; 155: 381–6CrossRef
9.
Yang C, Chung J, Yang G, et al. Tea and tea polyphenols in cancer prevention. J Nutr 2000; 130: 472S–8SPubMed
10.
Nakachi K, Matsuyama S, Miyake S, et al. Preventive effects of drinking green tea on cancer and cardiovascular disease: epidemiological evidence for multiple targeting prevention. Bio-factors 2000; 13: 49–54
11.
Hegarty V, May H, Khaw K. Tea drinking and bone mineral density in older women. Am J Clin Nutr 2000; 71: 1003–7PubMed
12.
Mikuls TR, Cerhan JR, Criswell LA, et al. Coffee, tea, and caffeine consumption and risk of rheumatoid arthritis. Arthritis Rheum 2002; 46: 83–91PubMedCrossRef
13.
Mukhtar H, Ahmad N. Tea polyphenols: prevention of cancer and optimizing health. Am J Clin Nutr 2000; 71 (6 Suppl.): 1698s–702sPubMed
14.
Murase T, Nagasawa A, Suzuki J, et al. Beneficial effects of tea catechins on diet-induced obesity: stimulation of lipid catabolism in the liver. Int J Obes Relat Metab Disord 2002; 26: 1459–64PubMedCrossRef
15.
Mack WJ, Preston-Martin S, Bernstein L, et al. Lifestyle and other risk factors for thyroid cancer in Los Angeles county females. Ann Epidemiol 2002; 12: 395–401PubMedCrossRef
16.
Mckay DL, Blumberg JB. The role of tea in human health: an update. J Am Coll Nutr 2002; 21: 1–13PubMed
17.
Kris-Etherton PM, Keen CL. Evidence that the antioxidant flavonoids in tea and cocoa are beneficial for cardiovascular health. Curr Opin Lipidol 2002; 13: 41–9PubMedCrossRef
18.
Wang SJ, Fuh JL, Teng EL, et al. A door-to-door survey of Parkinson’s disease in a Chinese population in Kinmen. Arch Neurology 1996; 53: 66–71CrossRef
19.
Chan DK, Woo J, Ho SC. Genetic and environmental risk factors for Parkinson’s disease in a Chinese population. J Neurol Neurosurg Psychiatry 1998; 65: 781–4PubMedCrossRef
20.
Ascherio A, Zhang SM, Hernan MA, et al. Prospective study of caffeine consumption and risk of Parkinson’s disease in men and women. Ann Neurol 2001; 50(1): 56–63PubMedCrossRef
21.
Levites Y, Weinreb O, Maor G, et al. Green tea polyphenol (−)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,-3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. J Neurochem 2001; 78(5): 1073–82PubMedCrossRef
22.
Nie GJ, Jin CF, Cao YL, et al. Distinct effects of tea catechins on 6-hydroxydopamine-induced apoptosis in PC12 cells. Arch Biochem Biophys 2002; 397(1): 84–97PubMedCrossRef
23.
Levites Y, Youdim MBH, Maor G, et al. Attenuation of 6-hydroxydopamine (6-OHDA)-induced nuclear factor-kappaB (NF-λB) activation and cell death by tea extracts in neuronal cultures. Biochem Pharmacol 2002; 63: 21–9PubMedCrossRef
24.
Ruan J, Wu X, Hardter R. Effects of potassium and magnesium nutrition on the quality components of different types of tea. J Sci Food Agric 1999; 79: 47–52CrossRef
25.
Lin YL, Juan IM, Chen Yl, et al. Composition of polyphenols in fresh tea leaves and associations of their oxygen-radical-absorbing capacity with antiproliferative actions in fibroblast cells. J Agric Food Chem 1996; 44: 1387–94CrossRef
26.
Liao S, Kao YH, Hiipakka RA. Green tea: biochemical and biological basis for health benefits. Vitam Horm 2001; 62: 1–62PubMedCrossRef
27.
Balentine DA, Wiseman SA, Bouwens LCM. The chemistry of tea flavonoids. Crit Rev Food Sci Nutr 1997; 37: 693–704PubMedCrossRef
28.
Yang GY, Liao J, Li C, et al. Effect of black and green tea polyphenols on c-jun phosphorylation and H2O2 production in transformed and non-transformed human bronchial cell lines: possible mechanisms of cell growth inhibition and apoptosis induction. Carcinogenesis 2000; 21: 2035–9PubMedCrossRef
29.
Borchers A, Keen CL, Hannum SM, et al. Cocoa and chocolate: composition, bioavailability, and health implications. J Med Food 2000; 3: 77–105CrossRef
30.
Pan TH, Fei J, Zhou XD, et al. Effects of green tea polyphenols on dopamine uptake and on MPP+-induced dopamine neuron injury. Life Sci 2003; 72: 1073–83PubMedCrossRef
31.
Yokogoshi H, Kobayashi M, Mochizuki M, et al. Effect of theanine, γ-glutamylethylamide, on brain monoamines and striatal dopamine release in conscious rats. Neurochem Res 1998; 23: 667–73PubMedCrossRef
32.
Yamane T, Nakatani H, Kikuoka N, et al. Inhibitory effects and toxicity of green tea polyphenols for gastrointestinal carcinogenesis. Cancer 1996; 77: 1662–7PubMed
33.
Li C, Lee MJ, Sheng S, et al. Structural identification of two metabolites of catechins and their kinetics in human urine and blood after tea ingestion. Chem Res Toxicol 2000; 13: 177–84PubMedCrossRef
34.
Pietta PG, Simonetti P, Gardana C, et al. Catechin metabolites after intake of green tea infusions. Biofactors 1998; 8: 111–8PubMedCrossRef
35.
Harada M, Kan Y, Naoki H, et al. Identification of the major antioxidative metabolites in biological fluids of the rat with ingested (+)-catechin an (−)-epicatechin. Biosci Biotechnol Biochem 1999; 63: 973–7PubMedCrossRef
36.
Manal M, Mohsen AE, Kuhnle G, et al. Uptake and metabolixm of epicatechin and its access to the brain after oral ingestion. Free Radic Biol Med 2002; 33: 1693–702CrossRef
37.
Datla KP, Christidou M, Widmer WW, et al. Tissue distribution and neuroprotective effects of citrus flavonoid tangeretin in a rat model of Parkinson’s disease. Neuroreport 2001; 12: 3871–5PubMedCrossRef
38.
Katiyar SK, Mukhtar H. Tea antioxidants in cancer chemoprevention. J Cell Biochem Suppl 1998; 27: 59–67
39.
Vinson J, Dabbagh Y, Serry M, et al. Plant flavonoids, especially tea flavonols, are powerful antioxidants using an in vitro oxidation model for heart disease. J Agric Food Chem 1995; 43: 2800–2CrossRef
40.
Middleton Jr E. Effect of plant flavonoids on immune and inflammatory cell function. Adv Exp Med Biol 1998; 439: 175–82PubMedCrossRef
41.
Eastwood MA. Interaction of dietary antioxidants in vivo: how fruit and vegetables prevent disease? QJM 1999; 92: 527–30PubMedCrossRef
42.
Hollman PC, Katan MB. Health effects and bioavailability of dietary flavonols. Free Radic Res 1999; 31: S75–80PubMedCrossRef
43.
Graham HN. Green tea composition, consumption, and polyphenol chemistry. Prev Med 1992; 21: 334–50PubMedCrossRef
44.
Ichihashi M, Ahmed NU, Budiyanto A, et al. Preventive effect of antioxidant on ultraviolet-induced skin cancer in mice. J Dermatol Sci 2000; 23: S45–50PubMedCrossRef
45.
Serafini M, Ghiselli A, Ferro-Luzzi A. In vivo antioxidant effect of green and black tea in man. Eur J Clin Nutr 1996; 50: 28–32PubMed
46.
Sano M, Takahashi Y, Yoshino K, et al. Effect of tea (Camellia Sinensis L.) on lipid peroxidation in rat liver and kidney: a comparison of green tea and black tea feeding. Biol Pharm Bull 1995; 18: 1006–8PubMedCrossRef
47.
Dreosti IE. Bioactive ingredients: antioxidants and polyphenols in tea. Nutr Rev 1996; 54: S51–8PubMedCrossRef
48.
Grinberg LK, Newmark H, Kitrossky N, et al. Protective effects of tea polyphenols against oxidative damage to red blood cells. Biochem Pharmacol 1997; 54(9): 973–8PubMedCrossRef
49.
Prystai EA, Kies CV, Driskell JA. Calcium, copper, iron, copper, iron magnesium and zinc utilization of humans as affected by consumption of black, decaffeinated black and green teas. Nutr Res 1999; 19: 167–77CrossRef
50.
Hayakawa F, Kimura T, Hoshino N, et al. DNA cleavage activities of (−)-epigallocatechin, (−)-epicatechin, (+)-catechin, and (−)-epigallocatechin gallate with various kind of metal ions. Biosci Biotechnol Biochem 1999; 63: 1654–6PubMedCrossRef
51.
Haslam E. Plant polyphenols-vegetable tannins revisited. Cambridge, UK: Cambridge University Press, 1989
52.
No JK, Soung DY, Kim YJ, et al. Inhibition of tyrosinase by green tea components. Life Sci 1999; 65(21): PL241–6PubMedCrossRef
53.
Akiyama K, Shimizu Y, Yokoi I, et al. Effects of epigallocatechin and epigallocatechin-3-O-gallate on catechol O-methyl-transferase. Neurosci 1989; 15: 262–4
54.
Dulloo AG, Seydoux J, Girardier L, et al. Green tea and therogenesis: interactions between catechin-polyphenols, caffeine and sympathetic activity. Int J Obes Relat Metab Disord 2000; 24: 252–8PubMedCrossRef
55.
Yoshizawa S, Horiuci T, Fujiki H, et al. Antitumor promoting activity of (−)-epigallocatechin gallate, the main constituent of “tannin” in green tea. Phytother Res 1987; 1: 44–7CrossRef
56.
Yasokawa M, Sugimoto I, Fukuma M, et al. (−)-Epigallocatechin gallate inhibits mos activation-mediated xenopus oocyte maturation induced by progesterone. FEBS Lett 1999; 463: 317–20PubMedCrossRef
57.
Levites Y, Amit T, Youdim MBH, et al. Involvement of protein kinase C activation and cell survival/cell cycle gene in green tea polyphenol (−)-Epigallocatechin-3-gallate neuroprotective action. J Biol Chem 2002; 277(34): 30574–80PubMedCrossRef
58.
Liu Z, Zhang J, Fei J, et al. A novel mechanism of dopamine neurotoxicity involving the peripheral extracellular and the plasma membrane dopamine transporter. Neuroreport 2001; 12(15): 3293–7PubMedCrossRef
59.
Pakkenberg B, Moller A, Gundersen HJ, et al. The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson’s disease estimated with an unbiased stereological method. J Neurol Neurosurg Psychiatry 1991; 54(1): 30–3PubMedCrossRef
60.
Maral Mouradian M. Recent advances in the genetics and pathogenesis of Parkinson disease. Neurology 2002; 58: 179–85PubMedCrossRef
61.
Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 1997; 276(5321): 2045–7PubMedCrossRef
62.
Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998; 392(6676): 605–8PubMedCrossRef
63.
Leroy E, Boyer R, Auburger G, et al. The ubiquitin pathway in Parkinson’s disease. Nature 1998; 395(6701): 451–2PubMedCrossRef
64.
Gorell JM, Johnson CC, Rybicki BA, et al. The risk of Parkinson’s disease with exposure to pesticides, farming, well water, and rural living. Neurology 1998; 50: 1346–50PubMedCrossRef
65.
Gerlach M, Gotz M, Dirr A, et al. Acute MPTP treatment produces no changes in mitochondrial complex activities and indices of oxidative damage in the common marmoset ex vivo one week after exposure to the toxin. Neurochem Int 1996; 28(1): 41–9PubMedCrossRef
66.
Singer TP, Castagnoli Jr N, Ramsay RR, et al. Biochemical events in the development of parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Neurochem 1987; 49(1): 1–8PubMedCrossRef
67.
Javitch JA, D’Amato RJ, Strittmatter SM, et al. Parkinsonism-inducing neurtotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahy-dropyridine: uptake of the metabolite N-methyl-4-phenylpyri-dine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci U S A 1985; 82: 2173–7PubMedCrossRef
68.
Nicklas WJ, Vyas I, Heikkila RE. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyri-dine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,-5,6-tetrahydropyridine. Life Sci 1985; 36(26): 2503–8PubMedCrossRef
69.
Bezard E, Gross CE, Fournier MC, et al. Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter. Exp Neurol 1999; 155: 268–73PubMedCrossRef
70.
Jenner P, Olanow CW. Understanding cell death in Parkinson’s disease. Ann Neurol 1998; 44 (3 Suppl. 1): S72–84PubMed
71.
Olanow CW, Tatton WG. Etiology and pathogenesis of Parkinson’s disease. Annu Rev Neurosci 1999; 22: 123–44PubMedCrossRef
72.
Le WD, Jankovic J. Are dopamine receptor agonists neuroprotective in Parkinson’s disease? Drugs Aging 2001; 18: 389–96PubMedCrossRef
73.
Halliwell B, Gutteridge JM. The importance of free radicals and catalytic metal ions in human diseases. Mol Aspects Med 1985; 8(2): 89–193PubMedCrossRef
74.
Olanow CW. A radical hypothesis for neurodegeneration. Trends Neurosci 1993; 16(11): 439–44PubMedCrossRef
75.
Sofic E, Lange KW, Jellinger K, et al. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson’s disease. Neurosci Lett 1992 Aug 17; 142(2): 128–30PubMedCrossRef
76.
Sian J, Dexter DT, Lees AJ, et al. Glutathione-related enzymes in brain in Parkinson’s disease. Ann Neurol 1994; 36(3): 356–61PubMedCrossRef
77.
Alam ZI, Jenner A, Daniel SE, et al. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem 1997; 69(3): 1196–203PubMedCrossRef
78.
Jenner P, Olanow CW. Oxidative stress and the pathogenesis of Parkinson’s disease. Neurology 1996; 47 (6 Suppl. 3): S161–70PubMedCrossRef
79.
Oliver CN, Starke-Reed PE, Stadtman ER, et al. Oxidative damage to brain proteins, loss of glutamine synthetase activity, and production of free radicals during ischemia/reperfusion-induced injury to gerbil brain. Proc Natl Acad Sci U S A 1990; 87: 5144–7PubMedCrossRef
80.
Matsuoka Y, Hasegawa H, Okuda S, et al. Ameliorative effects of tea catechins on active oxygen-related nerve cell injuries. J Pharmacol Exp Ther 1995; 274: 602–8PubMed
81.
Lee SR, Suhb SI, Kimc SP. Protective effect of the green tea polyphenol (−)- epigallocatechin gallate against hippocampal neuronal damage after transient global ischemia in gerbils. Neurosci Lett 2000; 287: 191–4PubMedCrossRef
82.
Guo Q, Zhao B, Li M, et al. Studies on protective mechanisms of four components of green tea polyphenols against lipid peroxidation in synaptosomes. Biochim Biophys Acta 1996; 1304(3): 210–22PubMedCrossRef
83.
Weinreb O, Mandel S, Youdim MBH. cDNA gene expression profile homology of antioxidants and their antiapoptotic and proapoptotic activities in human neuroblastoma cells. FASEB J 2003 May; 17(8): 935–7PubMed
84.
85.
Ricaurte GA, Langston JW, Delanney LE, et al. Dopamine uptake blockers protect against the dopamine depleting effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse striatum. Neurosci Lett 1985; 59: 259–64PubMedCrossRef
86.
Kitayama S, Wang JB, Uhl GR. Dopamine transporter mutants selectively enhance MPP+ transport. Synapses 1993; 15: 58–62CrossRef
87.
Jaber M, Jones S, Giros B, et al. The dopamine transporter: a crucial component regulating dopamine transmission. Mov Disord 1997; 12: 629–33PubMedCrossRef
88.
Yokozawa T, Dong E, Nakagawa T, et al. In vitro and in vivo studies on the radical-scavenging activity of tea. J Agric Food Chem 1998; 46: 2143–50CrossRef
89.
Langley-Evans S. Antioxidant potential of green and black tea determined using the ferric reducing power (FRAP) assay. Int J Food Sci Nutr 2000; 51: 181–8PubMedCrossRef
90.
Nakagawa K, Miyazawa T. Absorption and distribution of tea catechin, (−)-Epigallocatechin-3-Gallate, in the rat. J Nutr Sci Vitaminol (Tokyo) 1997; 43: 679–84CrossRef
91.
Suganuma M, Okabe S, Oniyama M, et al. Wide distribution of [3H] (−)-epigallocatechin gallate, a cancer preventive tea polyphenol, in mouse tissue. Carcinogenesis 1998; 19: 1771–6PubMedCrossRef
92.
Ebadi M, Srinivasan SK, Baxi MD. Oxidative stress and antioxidant therapy in Parkinson’s disease. Prog Neurobiol 1996; 48: 1–19PubMedCrossRef
93.
94.
Giros B, Jaber M, Jones SR, et al. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996; 379: 606–12PubMedCrossRef
95.
Pifl C, Giros B, Caron MG. Dopamine transporter -expression confers cytotoxicity to low dosed of the Parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium. J Neurosci 1993; 13: 4246–53PubMed
Metadaten
Titel
Potential Therapeutic Properties of Green Tea Polyphenols in Parkinson’s Disease
verfasst von
Tianhong Pan
Joseph Jankovic
Dr Weidong Le
Publikationsdatum
01.08.2003
Verlag
Springer International Publishing
Erschienen in
Drugs & Aging / Ausgabe 10/2003
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200320100-00001

Weitere Artikel der Ausgabe 10/2003

Drugs & Aging 10/2003 Zur Ausgabe

Original Research Article

A Long-Term Comparison of Galantamine and Donepezil in the Treatment of Alzheimer’s Disease

Review Article

Pharmacological Factors Influencing Anticancer Drug Selection in the Elderly

Therapy In Practice

Methotrexate Intolerance in Elderly Patients with Rheumatoid Arthritis

Original Research Article

Identification of Adverse Drug Reactions in Geriatric Inpatients Using a Computerised Drug Database

Original Research Article

Levocarnitine Administration in Elderly Subjects with Rapid Muscle Fatigue

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise